Área Sanitaria de Vigo
Área sanitaria
Johns Hopkins University School of Medicine
Baltimore, Estados UnidosPublicacións en colaboración con investigadores/as de Johns Hopkins University School of Medicine (13)
2023
2022
-
Common variants in breast cancer risk loci predispose to distinct tumor subtypes
Breast Cancer Research, Vol. 24, Núm. 1
-
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study
The Lancet Rheumatology, Vol. 4, Núm. 6, pp. e441-e449
2021
-
Assessing eligibility for differentiated service delivery, HIV services utilization and virologic outcomes of adult HIV-infected patients in Sierra Leone: a pre-implementation analysis
Global Health Action, Vol. 14, Núm. 1
-
Impact of subspecialty training on management of laryngopharyngeal reflux: results of a worldwide survey
European Archives of Oto-Rhino-Laryngology, Vol. 278, Núm. 6, pp. 1933-1943
-
Management of Laryngopharyngeal Reflux Around the World: An International Study
Laryngoscope, Vol. 131, Núm. 5, pp. E1589-E1597
-
Prevalence of hepatitis B surface antigen and serological markers of other endemic infections in HIV-infected children, adolescents and pregnant women in Sierra Leone: A cross-sectional study
International Journal of Infectious Diseases, Vol. 102, pp. 45-52
2020
-
Diagnosis and treatment outcomes of adult tuberculosis in an urban setting with high HIV prevalence in Sierra Leone: A retrospective study
International Journal of Infectious Diseases, Vol. 96, pp. 112-118
2018
-
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer
Nature Genetics, Vol. 50, Núm. 7, pp. 968-978
-
Influence of age, body mass index and comorbidity on major outcomes in acute pancreatitis, a prospective nation-wide multicentre study
United European Gastroenterology Journal, Vol. 6, Núm. 10, pp. 1508-1518
2017
-
Association analysis identifies 65 new breast cancer risk loci
Nature, Vol. 551, Núm. 7678, pp. 92-94
-
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
Arthritis and Rheumatology, Vol. 69, Núm. 2, pp. 362-375